Quantum Biopharma (QNTM) Long-Term Deferred Tax (2021 - 2025)

Quantum Biopharma has disclosed Long-Term Deferred Tax across 5 years of filings, most recently posting $1.2 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $1.2 million, down 98.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (down 98.86% YoY), and the FY2025 annual result was $1.2 million, down 98.86% from the prior year.
• Long-Term Deferred Tax came in at $1.2 million for Q4 2025 at Quantum Biopharma, down from $109.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $109.1 million in Q4 2024 to a low of $1.2 million in Q4 2025.
• The 5-year median for Long-Term Deferred Tax is $90.4 million (2022), against an average of $76.0 million.
• Across the five-year window, Long-Term Deferred Tax grew 16.94% in 2022 and plunged 98.86% in 2025, its largest moves.
• Quantum Biopharma's Long-Term Deferred Tax stood at $77.3 million in 2021, then increased by 16.94% to $90.4 million in 2022, then gained by 12.7% to $101.9 million in 2023, then gained by 7.03% to $109.1 million in 2024, then slumped by 98.86% to $1.2 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $1.2 million (Q4 2025), $109.1 million (Q4 2024), and $101.9 million (Q4 2023), per Business Quant data.